195 related articles for article (PubMed ID: 20379846)
1. The ErbB3 binding protein EBP1 regulates ErbB2 protein levels and tamoxifen sensitivity in breast cancer cells.
Lu Y; Zhou H; Chen W; Zhang Y; Hamburger AW
Breast Cancer Res Treat; 2011 Feb; 126(1):27-36. PubMed ID: 20379846
[TBL] [Abstract][Full Text] [Related]
2. Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.
Ghosh A; Awasthi S; Peterson JR; Hamburger AW
Br J Cancer; 2013 Feb; 108(3):557-63. PubMed ID: 23361053
[TBL] [Abstract][Full Text] [Related]
3. ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism.
Ghosh A; Awasthi S; Hamburger AW
Oncol Rep; 2013 Mar; 29(3):1161-6. PubMed ID: 23242156
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1.
Zhang Y; Akinmade D; Hamburger AW
Cancer Lett; 2008 Jul; 265(2):298-306. PubMed ID: 18355957
[TBL] [Abstract][Full Text] [Related]
5. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
6. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
7. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance.
Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW
Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121
[TBL] [Abstract][Full Text] [Related]
8. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
Hamburger AW
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):225-33. PubMed ID: 18425425
[TBL] [Abstract][Full Text] [Related]
9. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
11. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
[TBL] [Abstract][Full Text] [Related]
12. [Relation between c-erbB1, c-erbB2, MAPK expression and resistance to tamoxifen in breast cancer cells in vitro].
Zhang QY; Zhao WH; Kang XM
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):826-30. PubMed ID: 17416003
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells.
Akinmade D; Talukder AH; Zhang Y; Luo WM; Kumar R; Hamburger AW
Br J Cancer; 2008 Mar; 98(6):1132-40. PubMed ID: 18283314
[TBL] [Abstract][Full Text] [Related]
14. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
Huang X; Gao L; Wang S; Lee CK; Ordentlich P; Liu B
Cancer Res; 2009 Nov; 69(21):8403-11. PubMed ID: 19826038
[TBL] [Abstract][Full Text] [Related]
16. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
17. Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation.
Kwon NH; Lee MR; Kong J; Park SK; Hwang BJ; Kim BG; Lee ES; Moon HG; Kim S
RNA Biol; 2018; 15(4-5):635-648. PubMed ID: 28816616
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
19. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
Zhang Y; Wang XW; Jelovac D; Nakanishi T; Yu MH; Akinmade D; Goloubeva O; Ross DD; Brodie A; Hamburger AW
Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9890-5. PubMed ID: 15994225
[TBL] [Abstract][Full Text] [Related]
20. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
